Collectively, although it is essential to acknowledge the inherent challenges in drawing definitive conclusions from the limited number of pathogenic variants identified, the findings are indicative that disruption of m6A regulator gene function may potentially influence the clinical outcomes of ALS patients, with RBMX emerging as a most prominent candidate. Here, METTL3 is linked to amyotrophic lateral sclerosis.